SeaCrest Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

SeaCrest Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-572	Closed	-$77K	–	2063
2019 Q1	$77K	Sell	572 -4	-0.7%	-$497	0.01%	792
2018 Q4	$56K	Sell	576 -123	-18%	-$14.5K	0.01%	860
2018 Q3	$97K	Hold	699	–	–	0.02%	752
2018 Q2	$87K	Sell	699 -93	-12%	-$10.9K	0.02%	775
2018 Q1	$88K	Buy	792 +351	+80%	+$42K	0.02%	749
2017 Q4	$53K	Buy	+441	New	+$53.7K	0.01%	934

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

SeaCrest Wealth Management's ALXN Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 572 shares — an estimated $77K sold.

SeaCrest Wealth Management first reported a position in ALXN in Q4 2017 and held it in 6 quarters. The position peaked at $97K in Q3 2018. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

SeaCrest Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 572 Alexion Pharmaceuticals shares in Q2 2019, an estimated $77K.
SeaCrest Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Alexion Pharmaceuticals position peaked at $97K in Q3 2018.
636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.